The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V34086 | CL2-SN-38 | 1036969-20-6 | CL2-SN-38 is a cleavable linker-drug conjugate used for the synthesis of antibody drug conjugates (ADC). |
|
V33342 | CL2A-SN-38 | 1279680-68-0 | CL2A-SN-38, an SN-38 (topoisomerase-I inhibitor) analogue, is a peptide-based drug linker used to synthesize antibody drug conjugates (ADC). |
|
V86117 | Cys-mc-MMAE | ||
|
V77113 | Cys-mcMMAD | Cys-mcMMAD may be utilized to conjugate antibodies. | |
|
V54787 | DBA-DM4 | 905449-84-5 | DBA-DM4 is a drug-linker conjugate, which is connected by the linker DBA and the toxic molecule DM4. |
|
V53086 | DBCO-(PEG)3-VC-PAB-MMAE | 2754384-60-4 | DBCO-(PEG)3-VC-PAB-MMAE is an active molecular conjugate (drug-linker conjugate for ADC). |
|
V101022 | DBCO-PEG3-Glu-Val-Cit-PABC-MMAE | 2861998-23-2 | DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker complex for ADC. |
|
V76162 | DBCO-PEG4-Ahx-DM1 | 2479378-44-2 | DBCO-PEG4-Ahx-DM1 is an active molecular conjugate (ADC) consisting of the tubulin inhibitor DM1 and the linker DBCO-PEG4-Ahx. |
|
V52443 | DBCO-PEG4-GGFG-Dxd | 2694856-51-2 | DBCO-PEG4-GGFG-Dxd is part of an antibody-active molecule conjugate, consisting of the DNA topoisomerase I inhibitor Dxd and the cleavable ADC (Antibody-drug conjugate) linker DBCO-PEG4-GGFG. |
|
V51228 | DBCO-PEG4-MMAF | 2360411-65-8 | drug-linker conjugate |
|
V76164 | DBCO-PEG4-VA-PBD | 2241644-09-5 | DBCO-PEG4-VA-PBD is an antibody-drug-conjugate/ADC, which is made up of the anti-tumor antibiotic Pyrrolobenzodiazepine (PBD) and DBCO-PEG4-VA. |
|
V51230 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | drug-linker conjugate |
|
V51215 | DBCO-PEG4-VC-PAB-DMEA-PNU-159682 | 2259318-56-2 | drug-linker conjugate for ADC |
|
V53308 | DBCO-PEG4-VC-PAB-MMAE | 2129164-91-4 | DBCO-PEG4-VC-PAB-MMAE consists of ADC Linker (DBCO-PEG4-VC-PAB) and tubulin polymerization inhibitor MMAE. |
|
V88387 | DBCO-Val-Cit-PAB-MMAE | 2768446-73-5 | DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate that can be used to synthesize ADC molecules. |
|
V51225 | DBM-MMAF | 1810001-93-4 | drug-linker conjugate |
|
V88388 | Deruxtecan analog 2 monoTFA | 2758874-59-6 | Deruxtecan analog 2 (monoTFA) is a homologue of Deruxtecan, which is a conjugate of ADC toxin DX-8951 derivative (Dxd) and ADC Linker. |
|
V79085 | Desmethyl Vc-seco-DUBA | Desmethyl Vc-seco-DUBA is made up of cleavable ADC (Antibody-drug conjugate) linker (Desmethyl Vc-seco) and DUBA, a DNA alkylating agent. | |
|
V54760 | DGN549-C | 2058075-34-4 | DGN549-C consists of the cleavable ADC (Antibody-drug conjugate) linker valine-alanine (va) and a PBD dimer. |
|
V54776 | DGN549-L | 1884276-68-9 | DGN549-L contains a cleavable ADC?linker and a DNA alkylating agent for antibody conjugation of lysine residues. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
